Dr. Reddy’s Laboratory (NYSE:RDY): What Deutsche Bank Is Saying About Their Stock


How Deutsche Bank Currently Rates Dr. Reddy’s Laboratory (NYSE:RDY)

Stock analysts at Deutsche Bank initiated coverage on Dr. Reddy’s Laboratory (NYSE:RDY) with Sell rating. This was distributed to Clients in recent note on Wednesday morning.

The stock decreased 0.04% or $0.02 on December 2, striking $48.04. Approximately 1,100 shares of stock traded hands. Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) has declined 10.12% since April 29, 2015 and is downtrending. It has underperformed by 9.92% the S&P500.

Dr. Reddy's Laboratory (NYSE:RDY): What Deutsche Bank Is Saying About Their Stock

Dr. Reddy’s Laboratories Limited is an integrated global pharmaceutical firm that is engaged in providing medicines. The company has a market cap of $8.25 billion. The Firm operates in three divisions: Global Generics, Pharmaceutical Services and Active Ingredients , and Proprietary Products. It has 22.32 P/E ratio. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

According to Zacks Investment Research, “Doctor Reddy’s is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection” Get a free copy of the Zacks research report on Dr.Reddy’s Laboratories Ltd (ADR) (RDY).